← All Sponsors
SPONSOR

Gustave Roussy, Cancer Campus, Grand Paris

Total Trials
9
Recruiting
9
Phases
Phase 2, Phase 3

Gustave Roussy, Cancer Campus, Grand Paris is a clinical research sponsor with 9 registered studies on ClinicalTrials.gov, of which 9 are actively recruiting participants. Research covers conditions including NSCLC (Advanced Non-small Cell Lung Cancer), Ovarian Cancer, Metastatic Cancer, Solid Tumor.

The trial portfolio spans Phase 2, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.

Frequently Asked Questions — Gustave Roussy, Cancer Campus, Grand Paris

How many clinical trials has Gustave Roussy, Cancer Campus, Grand Paris sponsored?
ClinicalMetric currently tracks 9 clinical trials sponsored by Gustave Roussy, Cancer Campus, Grand Paris, of which 9 are actively recruiting participants. These trials cover conditions including NSCLC (Advanced Non-small Cell Lung Cancer), Ovarian Cancer, Metastatic Cancer. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Gustave Roussy, Cancer Campus, Grand Paris research focus on?
Gustave Roussy, Cancer Campus, Grand Paris clinical trials span NSCLC (Advanced Non-small Cell Lung Cancer), Ovarian Cancer, Metastatic Cancer, Solid Tumor, Leukemia, and additional conditions. The research pipeline includes Phase 2, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Gustave Roussy, Cancer Campus, Grand Paris clinical trial?
To participate in a Gustave Roussy, Cancer Campus, Grand Paris trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Gustave Roussy, Cancer Campus, Grand Paris trials with current recruitment status updated daily.

Clinical Trials by Gustave Roussy, Cancer Campus, Grand Paris

NCT07001618 Phase 2
Recruiting

Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer

NSCLC (Advanced Non-small Cell Lung Cancer)
NCT03010124
Recruiting

Prognostic and Predictive Biomarkers in Ovarian Cancers

Ovarian Cancer
NCT05283044
Recruiting

Implementing Precision Medicine in cOmmunity HospiTALs

Metastatic Cancer
NCT05691608
Recruiting

MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2

Solid Tumor
NCT03406247 Phase 2
Recruiting

Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma
NCT04224389
Recruiting

IMRT and Primary Transoral Surgery in the Treatment of Squamous Cell Carcinomas

Squamous Cell Carcinoma
NCT07512882
Recruiting

Cohort of Patients With Chronic Myelomonocytic Leukemia

Leukemia
NCT04965766 Phase 2
Recruiting

Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer
NCT05476939 Phase 3
Recruiting

Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0

Diffuse Intrinsic Pontine Glioma
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology